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Abstract
The purpose of this study was to identify factors associated with relapses or re-infections in patients with recurring Clostridium difﬁcile
infections (CDIs). From September 2008 to January 2012, cases with two or more isolates from consecutive CDI episodes were included.
PCR-ribotyping and multilocus variable-number tandem-repeat analysis were performed using paired isolates. Among 473 patients, 68
(14.4%) experienced one to ﬁve recurrences. Fifty-one of these with two or more isolates from consecutive CDI episodes were included in
the study; 25 (49%) were classiﬁed as relapses and 26 (51%) as re-infections. Recurrence interval was shorter in the relapse group (26.0
versus 67.5 p 0.001), but more patients in the re-infection group were hospitalized during recurrence interval (53.8% versus 8.0%,
p <0.001). Relapse rates in infections by ribotype 017, ribotype 018 and other ribotypes were 63.6%, 63.6% and 22.2%, respectively
(p 0.274, p 0.069, and p 0.005). In multivariate logistic regression, infections by ribotypes 017 and 018 were associated with CDI relapse
(OR 4.77, 95% CI 1.02–22.31, p 0.047; OR 11.49, 95% CI 2.07–63.72, p 0.005). Conversely, admission during recurrence interval lowered
the risk of relapse (OR 0.044, 95% CI 0.006–0.344, p 0.003). In conclusion, relapse was more likely when infection was caused by PCR
ribotypes 017 and 018.
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Introduction
Clostridium difﬁcile infection (CDI) is a common health-
care-associated infection with a recurrence rate of up to
36% among initially treated patients [1]. Age over 65 years,
severe underlying disease, use of antibiotics for non-CDIs or
proton-pump inhibitor and previous hospital exposure are
some of the recognized risk factors for recurrence. In
addition, infection with the BI/NAP1/027 strain has been
associated with risk of relapse [2,3]. Recurrence of CDI can
be caused by the original infecting strains (relapse) or by
another strain (re-infection). When molecular typing methods
were ﬁrst employed to identify strains, 50–90% of recur-
rences were conﬁrmed as relapses [1,2,4]. In the era before
the hypervirulent BI/NAP1/027 strain, two studies identiﬁed
C. difﬁcile strains by PCR-ribotyping [2,4]; in one report,
51.6% of recurrences were relapses [2], and as many as 90%
were relapses in the other report, mostly caused by the
dominant strain SE17 [4]. Since the start of the epidemic era,
a study using the multilocus variable-number tandem-repeat
analysis (MLVA) method and tcdC genotyping found that
62.2% of recurrences were relapses [1]. Infection with the BI/
NAP1/027 epidemic clone was a signiﬁcant risk factor for
relapse [1,5,6]. However, considering relapse of dominant
strains circulating in a society, care should be taken that the
dominance of common genotype strains may result in an
underestimate of re-infection with different lineages of the
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same genotype [5]. In Korea, PCR ribotypes 017 and 018
were found to be responsible for 42% of hospital-acquired
CDIs, whereas the proportion of BI/NAP1/027 strain was
very low [7]. The PCR ribotype 017 strains are toxin A
negative and toxin B positive, toxinotype VIII strains, and are
known to be endemic or to have caused epidemics in Asian
countries such as Korea or China and across the world [7–
12]. Ribotype 018 isolates are toxin A and toxin B positive,
and is the most common ribotype in Japan, Korea and Italy
[7,10,13]. Ribotype 017 infection caused a higher mortality,
comparable to that of ribotype 027, than those of other
ribotypes in one report [11], and clindamycin use was a
signiﬁcant associated factor [7,11]. Both ribotype isolates
were known to have a high resistance rate to clindamycin and
ﬂuoroquinolones, which could contribute to their enhanced
virulence [7,10,14,15].
The aim of our study was to determine the frequency of
CDI relapses in an area without epidemic BI/NAP1/027, and to
compare relapse rates between different PCR-ribotypes. In
addition, we would like to identify the clinical characteristics
and risk factors speciﬁcally associated with relapse or
re-infection. To achieve this, we performed PCR-ribotyping
and MLVA of paired isolates of C. difﬁcile from different
episodes of CDI in individual patients, and compared their
clinical characteristics.
Materials and Methods
Patients and study design
From September 2008 to January 2012, conﬁrmed CDI
episodes were reviewed, and patients who had experienced
more than two episodes were enrolled. Of the enrolled cases,
those with at least two cultured C. difﬁcile isolates from
different CDI episodes were included in this study. The study
was approved by the Institutional Review Board of Hanyang
University Hospital (HYUH IRB 2012-07-023). Informed
consent was waived by the Board.
Deﬁnitions
Diarrhoea was deﬁned as unformed stools more than three
times per day on consecutive days, and CDI was conﬁrmed
when toxin genes (tcdA, tcdB, cdtA or cdtB) from C. difﬁcile
isolates were identiﬁed in patients with diarrhoea by multiplex
PCR, the toxin assay A&B (VIDAS C. difﬁcile Toxin A & B;
BioMerieux SA, Marcy l’Etoile, France) yielded positive results,
and/or pseudomembranes were seen by endoscopy or
histology [16]. Healthcare-associated CDI was conﬁrmed in
patients who developed diarrhoea at least 72 h after
hospitalization or within 2 months of their last discharge
[17]. Recurrence was deﬁned as a resurgence of symptoms
with positive C. difﬁcile results, after cessation of treatment
and at least 10 days after the ﬁrst episode [2]. Using paired
isolates of C. difﬁcile, MLVA using the six variable-number
tandem repeat loci of CDR4, CDR5, CDR9, CDR48, CDR49
and CDR60 was performed as described elsewhere [18,19];
relapse was deﬁned when the sum of tandem-repeat
differences (STRD) of the two consecutive isolates was ≤2,
provided that isolates were single locus variants or double
locus variants of one another [9,18]. Cases with STRD ≥3
were considered as re-infections.
The interval between the initial onset CDI and the onset of
the next episode was deﬁned as the recurrence interval. It was
divided into two periods: period 1 included the initial CDI
treatment, and period 2 was from completion of CDI
treatment to the day of recurrence.
Data collection
Medical records were reviewed retrospectively. Age, sex,
length of hospital stay, history of operations within the past
2 months, and underlying disease including Charlson score
were collected as demographic data. Among the clinical
characteristics, CDI disease severity was assessed using the
sum of scores ascribed to the following factors (1 point
each): age >60 years, temperature >38.3°C, albumin level
<2.5 mg/dL, or white blood cell count ≥15 000 cells/lL.
When the score was ≥2, disease was regarded as severe
[20].
The number of hospital admissions and length of hospital
stays during the recurrence interval were recorded. Use of
antibiotics including treatment for CDI, probiotics, pro-
ton-pump inhibitor, H2 blocker, steroids, analgesics including
opioids, laxatives, or mucolytics during periods 1 and 2 was
evaluated. The quantity of antibiotics taken by each patient was
expressed as the number of deﬁned daily dose, i.e. the total
quantity of antibiotic divided by the deﬁned daily dose [21]. For
recurrence intervals longer than 2 months, we investigated the
use of medication during the 2 months immediately before the
recurrence.
Isolation of Clostridium difﬁcile and multiplex PCR for toxin
genes
Stool specimens were cultured anaerobically on cycloserine–
cefoxitin–taurocholate agar (Oxoid Ltd., Cambridge, UK)
supplemented with 7% horse blood after alcohol shock
treatment. Colonies of C. difﬁcile were identiﬁed with an API
Rapid ID 32A system (BioMerieux SA, Lyon, France). With
template DNA, multiplex PCR and agar gel electrophoresis
were performed as described elsewhere with minor
modiﬁcation [22].
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PCR-ribotyping of Clostridium difﬁcile
PCR-ribotyping was performed using template DNA as
described elsewhere [23]. Banding patterns were checked
visually. Each unique pattern was assigned its own ribotype
code and was matched with the PCR-ribotypes of the
reference strains ribotype 027 (BI/NAP1/027), ribotype 017
(ATCC 43598) and standard strains from the ECDC-Brazier
collection.
Multilocus variable-number tandem repeat analysis
When an isolate from a patient with recurring CDI showed
an identical PCR-ribotype to that of the ﬁrst episode, MLVA
was performed using the six variable-number tandem repeat
loci: CDR4, CDR5, CDR9, CDR48, CDR49 and CDR60, as
described elsewhere [18,19]. The genetic relationships among
the genotypes were determined by clustering them according
to MLVA type using the number of differing loci and the
summed absolute distance as coefﬁcients for calculating the
minimum spanning tree as described [18], using BIONUMERICS
software (Version 5.0; Applied Maths NV, Sint-Mar-
tens-Latem, Belgium). Relapse was deﬁned when the STRD
of the two consecutive isolates was ≤2, provided that isolates
were single locus variants or double locus variants of one
another [18,19]. Cases with STRD ≥3 were considered as
re-infections.
Statistical methods
IBM SPSS version 21.0 for Windows (SPSS Inc., Chicago, IL,
USA) was used for statistical analysis. Pearson’s chi-square test
or Fisher’s exact test was used to analyse categorical variables,
and the independent t-test or Mann–Whitney U-test was used
to analyse continuous variables. Odds ratios (OR) with 95% CI
were calculated for all signiﬁcant variables. Multiple logistic
regression was performed to identify factors associated with
relapse or re-infection. Recurrence intervals were calculated
by the Kaplan–Meier method. p-values <0.05 in two-tailed
tests were considered statistically signiﬁcant.
Results
Study population and distribution of ribotypes
Over the study period, 473 patients experienced a total of 558
episodes conﬁrmed as CDI. Of 473 patients, 68 (14.4%)
experienced between one and ﬁve recurring episodes: 51
(75.0%) had one recurring episode, 13 (19.1%) had two, 1
(1.5%) had three, 2 (2.9%) had four, and 1 (1.5%) had ﬁve. Of
68 patients, 51 patients had at least two isolates, one per
episode from two consecutive CDIs, and they were enrolled
for the study.
The most common PCR ribotypes among a total of 119
isolates from 51 patients were 018 (41.2%), 017 (24.4%) and
001 (9.2%). Ribotype 017 isolates were all toxin A negative and
toxin B positive, ﬁve isolates (two of ribotype 027, two of
ribotype 078 and one of unmatched ribotype) were toxin A,
toxin B and binary toxin positive and the other isolates were
all toxin A and toxin B positive.
Among the 51 patients, 19 had different PCR-ribotypes in
the consecutive isolates, and 32 had identical PCR-ribotypes.
To further analyse the latter, MLVA was performed. Seven
cases in this group (21.9%) had an STRD of 3–41 and
were classiﬁed as re-infections (Table 1). Overall, 25
relapses (49.0%) and 26 re-infections (51.0%) were identi-
ﬁed.
Clinical and microbiological characteristics of CDI relapse
and re-infection
Table 2 presents the demographic and clinical characteristics
of the relapse and re-infection patients. There was no
difference in age, gender and Charlson score between the
groups. Likewise, there was no signiﬁcant difference in disease
severity between the groups or between the ﬁrst and second
episodes of CDI in each group. The ﬁrst episode of CDI was
treated with metronidazole in all cases. Treatment duration
and the quantity of metronidazole and vancomycin did not
differ between the groups.
We investigated histories of medication use during both
periods of the recurrence interval. In terms of non-antibiotic
medication, there was no difference between the relapse and
re-infection groups (data not shown), and antibiotics not
targeting CDI were also used similarly in the relapse
and re-infection groups during period 1 and period 2
(Table 2).
We compared relapse rates among infections of ribotype
017, ribotype 018 and other ribotypes (Table 2). In the
PCR-ribotype 017 group, seven out of 11 (63.6%) recurring
episodes were classiﬁed as relapse (p 0.274) and 14 out of 22
(63.6%) were relapse in the ribotype 018 group (p 0.069).
Conversely, four out of 18 (22.2%) recurrences caused by
other ribotypes were relapses (p 0.005).
Recurrence interval and hospitalization in the relapse and
re-infection group
Table 2 shows the recurrence interval of relapse and re-infec-
tion groups. The median interval to recurrence was 26 days
(1Q, 3Q: 15.5, 49.0) in patients with a relapse, and 67.5 days
(1Q, 3Q: 31, 147.3) in patients with re-infection (p 0.001).
When the groups were compared at the 30-day points, the
distribution of recurrence was signiﬁcantly different (p for
trend <0.001; Table 2 and Fig. 1).
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TABLE 1. PCR-ribotypes and multilocus variable number of tandem repeat analysis results of Clostridium difﬁcile isolates from
consecutive C. difﬁcile infections (CDI)
First episode
Second episode
001 002 012 014 015 017 018 027 078 112 163 Others Others1c Subtotal
001 3/1 a 1 5
002 1 1 2
012 1 1
014 1 1 2
015 0
017 7/2 2 11
018 1 1 12/4 1 1 1 21
027 0
078 0
112 1/0 1
163 0
Other 1b 1b 2b 2/0 2c 8
Subtotal 5 0 0 1 1 12 22 1 1 2 1 3 2 51
aN/N, number of the highly related multilocus variable number of tandem repeat analysis (MLVA) genotypes/different MLVA genotypes
bDiscriminant but unmatched PCR-ribotype results with reference strains.
cTwo patients with C. difﬁcile isolates of unmatched ribotypes with reference strains at initial C. difﬁcile infection (CDI) showed discriminant but unmatched PCR-ribotypes in
recurrent episode of CDI.
The grey shades indicate that the isolates from the initial and consecutive episodes of CDI showed identical PCR-ribotype.
TABLE 2. Demographic and clinical characteristics of Clostridium difﬁcile relapses and
re-infections
Relapse
25
Re-infection
26 p-value
Demographic factors
Sex, male n (%) 12 (48.0) 9 (34.6) 0.332
Age, median (1Q, 3Q) 75.0 (67.5, 82.5) 72.0 (60.3, 81.3) 0.833
Age >65, n (%) 20 (80.0) 18 (69.2) 0.378
Charlson score, median (1Q, 3Q) 4.0 (2.0, 5.5) 3.0 (2.0, 6.0) 0.962
Nasogastric tube, n (%) 10 (40.0) 10 (38.5) 0.910
Renal replacement therapy, n (%) 2 (8.0) 3 (11.5) 1.000
Chemotherapy, n (%) 5 (20.0) 5 (19.2) 1.000
Proton-pump inhibitor, n (%) 21 (84.0) 19 (73.1) 0.343
CDI disease severity score
1st episode, median (1Q, 3Q) 1.0 (1.0, 2.0) 1.0 (0.0, 2.0) 0.261
Severe CDI in 1st episode, n (%) 9 (36.0) 8 (30.8) 0.692
2nd episode, median (1Q, 3Q) 2.0 (1.0, 2.0) 1.0 (0.8, 2.0) 0.301
Severe CDI in 2nd episode, n (%) 14 (56.0) 9 (34.6) 0.125
Difference between 1st and
2nd episode, median (1Q, 3Q)
0.0 (1.0, 0.0) 0.0 (1.0, 0.0) 0.679
Recurrence interval, median (1Q, 3Q) 26.0 (15.5, 49.0) 67.5 (31.0, 147.3) 0.001
≤30 days, n (%) 15 (60.0) 5 (19.2) <0.001a
31–60 days, n (%) 5 (20.0) 7 (26.9)
61–90 days, n (%) 5 (20.0) 5 (19.2)
91–120 days, n (%) 0 (0.0) 1 (3.8)
≥121 days, n (%) 0 (0.0) 8 (30.8)
Recurrent interval >60 days, n (%) 5 (20.0) 14 (53.8) 0.012
During recurrence interval
Length of hospital stay (days), median (1Q, 3Q) 20.0 (12.0, 40.0) 36.0 (16.8, 73.8) 0.111
No. of admissions per patient, median (1Q, 3Q) 0.0 (0.0, 0.0) 1.0 (0.0, 1.3) 0.001
History of admission, n (%) 2 (8.0) 14 (53.8) <0.001
PCR-ribotype, n (%) b
017 7/11 (63.6) 4/11 (36.4) 0.274
018 14/22 (63.6) 8/22 (36.4) 0.069
Others 4/18 (22.2) 14/18 (77.8) 0.005
Medication history during CDI treatment (period 1)
CDI treatment change, n (%) 3 (12.0) 6 (25.0) 0.289
CDI treatment duration (days), median (1Q, 3Q) 10.0 (7.0, 13.0) 11.5 (9.0, 16.0) 0.241
CDI treatment quantity (DDD), median (1Q, 3Q) 7.5 (5.0, 9.8) 7.5 (5.3, 9.9) 0.932
Non-CDI antimicrobial agent use, n (%) 20 (80.0) 15 (57.7) 0.086
Medication history during recurrence interval (period 2)
Antimicrobial agents, n (%) 18 (72.0) 18 (69.2) 0.828
No. of antimicrobial agents, median (1Q, 3Q) 2.0 (0.0, 3.0) 1.5 (0.0, 4.0) 0.923
Quantity of antimicrobial agents (DDD), median (1Q, 3Q) 6.0 (0.0, 22.9) 19.6 (0.0, 40.5) 0.330
Class of antimicrobial agents, n (%)
BLI 5 (20.0) 7 (26.9) 0.560
Fluoroquinolones 11 (44.0) 7 (26.9) 0.202
ESC 4 (16.0) 8 (30.8) 0.214
BLI, b-lactam/b-lactamase inhibitors; CDI, C. difﬁcile infection; DDD, deﬁned daily dosing; ESC, extended spectrum
cephalosporins
ap for trend.
bPercentage of relapse or re-infection among
ribotypes 017, 018 and others.
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The total number of days spent in the hospital during the
recurrence interval did not differ between the groups (20
versus 36 days, p 0.11). However, the number of admissions
per patient and the number of admitted patients during the
recurrence interval were higher in the re-infection group than
in the relapse group (median number of admissions (1Q, 3Q),
1 (0, 1.3) versus 0 (0, 0), p 0.001; number of admitted patients
during recurrence interval, 14/26 (53.8%) versus 2/25 (8.0%),
p <0.001; Table 2).
Factors associated with relapse among patients with
recurring CDI
To identify the risk factors associated with relapse, a multiple
regression analysis was performed using clinical, historical and
microbiological variables ﬁrst identiﬁed in univariate analysis
(Table 3). The ﬁnal multiple logistic regression model included
history of re-admission before recurrence, infections caused
by ribotype 017, infections caused by ribotype 018, recurrence
interval >60 days, and use of non-CDI antimicrobials during
period 2. In this model, infections caused by ribotype 017 and
ribotype 018 were the signiﬁcant predictors of relapse in
patients with recurring CDI (OR = 4.77, 95% CI 1.02–22.31,
p 0.047; OR = 11.49, 95% CI 2.07–63.72, p 0.005,
respectively). Conversely, history of admission during recur-
rence interval lowered the risk of relapse (OR = 0.044, 95%
CI 0.006–0.344, p 0.003).
Case studies with multiple recurrences of CDI
Among 17 cases experiencing at least two recurrences,
isolates of 10 patients were available from subsequent CDI
recurrences. Patients 3, 4, 5, 7 and 8 experienced mixed
episodes of relapse and re-infection, while patients 2 and 6
only had relapses, and patients 1, 9 and 10 only had
re-infections. Fig. 2 shows the detailed relationships between
MLVA genotypes from nine patients (excluding patient 10)
with at least two recurring episodes of CDI.
Discussion
In this study, metrics used to conﬁrm relapse or re-infection
were the results of PCR-ribotyping and MLVA genotyping. The
proportion of relapse among all recurrence in our study was
similar to a report using PCR-ribotyping and serotyping to
classify recurrence [2], but lower than a study from the USA
with higher prevalence of BI/NAP1/ribotype 027 strain [1]. In
areas with a high prevalence of C. difﬁcile PCR-ribotype 027,
infection by these strains was identiﬁed as a risk factor for
recurrence, and especially for relapse [1,5,6,24,25]. As we
reported previously, the dominant strains in our institution in
2009 were PCR-ribotypes 018 and 017 [7], and their
frequency has increased over the past 3 years. Our results
demonstrated that infection by PCR-ribotypes 017 and 018 is
a signiﬁcant predictor of relapse. Unlike PCR-ribotype 027
strains, which were identiﬁed as more virulent [6,26], the
virulence of PCR-ribotype 018 and 017 has not been clearly
deﬁned [11]. Comparative study for clinical outcome between
infections by ribotypes 017/018 and other ribotypes is
warranted. Nevertheless, relapse estimates may be affected
by the underlying population structure, as initial infection with
the commonly circulating strain in a hospital tends to lead to
FIG. 1. Kaplan–Meier plot of the recurrence interval in patients with
relapse and re-infection.
TABLE 3. Factors associated with
relapse in recurring Clostridium difﬁ-
cile infection (CDI) episodes
Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
History of re-admission before recurrence 0.075 (0.014–0.38) 0.002 0.044 (0.006–0.344) 0.003
PCR-ribotype 017 2.14 (0.54–8.48) 0.279 4.77 (1.02–22.31) 0.047
PCR-ribotype 018 2.86 (0.91–9.02) 0.072 11.49 (2.07–63.72) 0.005
Recurrence interval >60 days 0.21 (0.062–0.75) 0.015 0.49 (0.11–2.29) 0.365
Non-CDI antimicrobial agent use 1.15 (0.78–1.71) 0.438 1.03 (0.22–4.83) 0.969
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higher estimated relapse rates as described [5]. Interestingly,
patients hospitalized during recurrence interval were more
likely to have re-infection than relapse in this study, which
clearly indicated that hospitalization increased the exposure to
C. difﬁcile.
Several studies have differentiated re-infection from relapse
using the interval between episodes as a guide; in these, two
episodes in the same patient that occurred between 8 weeks
and 3 months apart were considered as distinct infections
[1,6,27,28]. In our study, most relapse cases occurred within
90 days, and recurrences after 3 months were all re-infec-
tions. However, a study with a large number of recurred cases
in an area with high prevalence of BI/NAP1/ribotype 027
strains reported that 30% of recurrence shared no sequence
types in common at 91 days and 40% at 183 days in multilocus
sequence typing analysis [5].
Our study has potential limitations. First, a small number of
recurrences were included, so its statistical power was
relatively low. Second, the recurrence rate could be under-
estimated because of the retrospective setting. Despite these
limitations, the study has several advantages; the clinical
characteristics including host factors, and medications and
disease history were obtained from all participating patients,
and the relapse/re-infection rates were determined at a
hospital with prevalent PCR-ribotypes other than PCR-ribo-
type 027.
In summary, this study distinguished CDI re-infections from
relapses using PCR-ribotyping and MLVA. In Korea where the
prevalence of the hypervirulent BI/NAP1/027 C. difﬁcile strain
is low, the only signiﬁcant predictor of relapse was infection
caused by PCR-ribotypes 017 and 018.
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